BIOPHARMA
ByCan Gilead Sustain Growth Beyond HIV and Hepatitis in 2026?
Late January 2026 | Full-Year 2025 Earnings Preview | Antivirals, Oncology & Emerging Therapies Gilead Sciences is set…
Is AstraZeneca Building the Most Diversified Growth Engine in Global Pharma?
Late January–Early February 2026 | Full-Year 2025 Earnings Preview | Oncology, CVRM & Platform Innovation AstraZeneca is expected…
Can Merck Redefine Its Growth Story Beyond Keytruda as the Patent Clock Ticks?
Late January 2026 | Full-Year 2025 Earnings Preview | Oncology, Vaccines & Post-Keytruda Strategy Merck & Co. (known…
Can Novo Nordisk Defend Its Obesity Crown as Competition With Eli Lilly Intensifies in 2026?
Late January 2026 | Full-Year 2025 Earnings Preview | Obesity & Metabolic Disease Strategy Novo Nordisk is set…
Sanofi’s $1.53B Sino Biopharm Pact: Strategic Power Play or China-Derisked Bet?
Sanofi’s March 3, 2026, licensing of Sino Biopharm’s rovadicitinib—a JAK1 inhibitor approved in China for first-line myelofibrosis—upfront $135M…
GLP-1s: The Thrilling Game-Changer in Obesity—Why Insurers Are Throwing Open the Reimbursement Gates
GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) are electrifying the obesity market with unprecedented 15-25% sustained…
